Uses
A independent have of cyclophosphamide is together by having more chemotherapy offices in the professional assistance of lymphomas, some forms of leukemia and some firm neoplasm.

Additionally, its utilise is becoming other green around autoimmune diseases where disease-modifying antirheumatic drugs (DMARDs) have been uneffective. Systemic lupus erythematosus (SLE) with severe lupus nephritis, for example, could respond to pulsed cyclophosphamide.

Pharmacokinetics
Cyclophosphamide is converted by mixed work oxidase enzymes in the liver to active metabolites. A independent active metabolite is Four-hydroxycyclophosphamide. Four-hydroxycyclophosphamide lives inside equilibrium with its tautomer, aldophosphamide. Virtually all of the aldophosphamide is oxidised per enzyme aldehyde dehydrogenase (ALDH) to make carboxyphosphamide. The little proportion of aldophosphamide is converted into phosphoramide mustard & propenal. Acrolein is toxic to the bladder epithelium and can lead to hemorrhagic cystitis.

Mode of action
A independent consequence of cyclophosphamide is due to its metabolite phosphoramide mustard. This metabolite is simply formed around cells which own online levels of aldehyde dehydrogenase.

Phosphoramide mustard forms DNA crosslinks between & in DNA strands. This leads to cell demise.

Cyclophosphamide hwhen comparatively little average chemotherapy toxicity, as ALDH is present inside comparatively big concentrations within bone marrow stem cells, liver and intestinal epithelium, protecting these tissues against phosphoramide mustard.

Side-effects
Side-effects include chemotherapy-induced nausea and vomiting (CINV), bone marrow suppression, alopecia (hair loss) and lethargy. Hemorrhagic cystitis occurs as frequent complication, however this is prevented by adequate fluid intake & mesna (sodium Two-mercaptoethane sulfonate). Mesna occurs as sulfhydryl donor & binds propenal.

Cyclophosphamide is itself carcinogenic, potentially stimulating transitional cell carcinoma of the bladder as a long-term complication.

History
Cyclophosphamide & a related nitrogen mustard-derived alkylating agent ifosfamide were developed by Norbert Brock and ASTA (nowadays Baxter Oncology). It converted the base nitrogen mustard into a non-nonpoisonous "transport form". This transfer form was the pro-drug, afterward actively transported into the cancer cells. Once in a cells, a pro-drug was enzymatically converted into the active, toxic form. Brock & his team synthesised to a higher degree 1,000 candidate oxazophosphorine compounds, one of these days sorting through a drug cyclophosphamide (Brock 1996).

Reference
Brock North. A history of the oxazaphosphorine cytostatics. Cancer 1996;78:542-7. PMID 8697402.

de:Cyclophosphamid ja:シクロホスファミド